BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15179405)

  • 1. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
    Sai K; Saeki M; Saito Y; Ozawa S; Katori N; Jinno H; Hasegawa R; Kaniwa N; Sawada J; Komamura K; Ueno K; Kamakura S; Kitakaze M; Kitamura Y; Kamatani N; Minami H; Ohtsu A; Shirao K; Yoshida T; Saijo N
    Clin Pharmacol Ther; 2004 Jun; 75(6):501-15. PubMed ID: 15179405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
    Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
    Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
    J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
    Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
    Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.
    Kaniwa N; Kurose K; Jinno H; Tanaka-Kagawa T; Saito Y; Saeki M; Sawada J; Tohkin M; Hasegawa R
    Drug Metab Dispos; 2005 Mar; 33(3):458-65. PubMed ID: 15572581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
    Wang H; Bian T; Jin T; Chen Y; Lin A; Chen C
    Pharmacogenomics; 2014 Apr; 15(6):785-98. PubMed ID: 24897286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
    Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
    Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
    Innocenti F; Grimsley C; Das S; Ramírez J; Cheng C; Kuttab-Boulos H; Ratain MJ; Di Rienzo A
    Pharmacogenetics; 2002 Dec; 12(9):725-33. PubMed ID: 12464801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
    Fujita K; Ando Y; Nagashima F; Yamamoto W; Eodo H; Araki K; Kodama K; Miya T; Narabayashi M; Sasaki Y
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):515-22. PubMed ID: 17406868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
    Sandanaraj E; Jada SR; Shu X; Lim R; Lee SC; Zhou Q; Zhou S; Goh BC; Chowbay B
    Pharmacogenomics J; 2008 Jun; 8(3):174-85. PubMed ID: 17700594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
    Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
    Onoue M; Inui K
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1080-5. PubMed ID: 18633245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
    Jinno H; Saeki M; Saito Y; Tanaka-Kagawa T; Hanioka N; Sai K; Kaniwa N; Ando M; Shirao K; Minami H; Ohtsu A; Yoshida T; Saijo N; Ozawa S; Sawada J
    J Pharmacol Exp Ther; 2003 Aug; 306(2):688-93. PubMed ID: 12730278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
    Liu Y; Ramírez J; House L; Ratain MJ
    Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.